Navigation Links
ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate
Date:8/21/2013

SAN DIEGO, Aug. 21, 2013 /PRNewswire/ -- The International Trade Commission has agreed to investigate Chinese medical device manufacturer BMC Medical Co., Ltd., and its distributors, Florida-based 3B Medical Inc. and 3B Products, L.L.C.. The Investigation was initiated at the request of ResMed (NYSE: RMD), a global innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions. ResMed also filed suit in federal court against BMC in May, asserting patent infringement by:

  • The RESmart CPAP and RESmart Auto CPAP devices, and
  • The Willow nasal pillows patient interface and the iVolve nasal mask.
  • (Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

    ResMed pursued a similar legal action earlier this year against Taiwanese manufacturer APEX Medical Corp. asserting patent infringement that resulted in APEX consenting to an order barring infringing products from the U.S. market.

    "We're encouraged by the ITC's action to investigate this case against BMC," said ResMed Global General Counsel and Chief Administrative Officer David Pendarvis. "For more than two decades, ResMed has generated significant advances in innovative products for sleep-disordered breathing therapy We invest over $100 million in research and development each year to fuel these advances and other companies should not be allowed to infringe ResMed's intellectual property by using our technology."

    About ResMed:
    ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative
    '/>"/>

    SOURCE ResMed Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
    2. ResMed Launches Narvalâ„¢ CC Mandibular Repositioning Device in the US
    3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
    4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
    5. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
    6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
    7. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
    8. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    9. ResMed Takes Action to Enforce Patents
    10. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
    11. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
    (Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    ... May 19, 2007 /PRNewswire/ -- Data presented,today at ... mg tablets administered once-daily for five days is ... for 10,days for the treatment of complicated urinary ... Inc., the company that markets LEVAQUIN in the,U.S., ...
    ... 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) reported ... trial evaluating Altace (ramipril) 20mg and the,combination ... were,presented this weekend at the American Society ... and Exposition,(ASH 2007) in Chicago, Illinois. The ...
    Cached Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 2King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 3King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 5
    (Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
    (Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
    (Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
    (Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
    (Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
    Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
    ... Pen ... Technology, ... system, a new innovative solution for,digitally capturing patient information that is ... administer. The Docuscan Patient History solution with Paros(TM) technology enables,digital ...
    ... pop stars are more than twice as likely as the ... within a few years of becoming famous, reveals research published ... Health. , The findings are based on more than 1050 ... fame between 1956 and 1999. , All the musicians featured ...
    ... Steps for Young Children Program, which added behavior ... benefit families more than two years after the ... from the Johns Hopkins Bloomberg School of Public ... Steps included greater satisfaction among parents with their ...
    ... give rise to exuberant scarring, which can lead to ... disfigurement. In a review article in this weeks PLoS ... of Medicine) and colleagues examine the process of such ... the research areas that are likely to lead to ...
    ... ARLINGTON, Va., Aug. 22 The American,Psychiatric Association (APA) ... review of scientific evidence that led to the,approval of ... The APA is pleased that the approvals are a ... which was designed to,encourage research that leads to this ...
    ... safety of blood supply by detecting virus ... earlier in infection cycle., ... & Drug Administration (FDA) today approved its biologics,license application for the ... blood and plasma. West Nile virus, which can,cause serious health issues, ...
    Cached Medicine News:Health News:New 'Smart' Technology Makes Patient Data Collection Easier, More Efficient 2Health News:Pop stars more than twice as likely to die an early death 2Health News:Practice-based intervention has sustained benefits for children and families 2Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 3
    ... American Proficiency Institute offers innovative proficiency ... technical support. As a result, API is ... in the world with over 12,000 laboratories ... advantages of using API:, Paperless ...
    ... APC-R FVL is a new functional test ... for Activated Protein C Resistance caused by ... contrast to other commercially available methods, Pefakit ... C or S, Lupus Anticoagulants, Elevated FVIII ...
    ... is an advanced ophthalmic laser platform, ... technologies, improved operability, fast operation, super ... with versatility for combination laser systems. ... and adds several unique features such ...
    The Properdin ELISA Kit is approved for in-vitro diagnostic use and measurement of properdin serum levels, relevant in cases of recurrent meningococcal infection and recurrent bacterial meningitis....
    Medicine Products: